4-Phenylazophenyl isothiocyanate | 7612-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: 4-Phenylazophenyl isothiocyanate
• 英文别名: 1-(4-isothiocyanatophenyl)-2-phenyldiazene；4-(phenylazo)phenyl isothiocyanate；4-Phenylazophenylisothiocyanate；trans-4-Isothiocyanato-azobenzol
• CAS: 7612-96-6
• 化学式: C₁₃H₉N₃S
• 分子量: 239.301
• InChiKey: ZTXNMMXJFVCQPD-FOCLMDBBSA-N

物化性质

• 熔点：
  94 °C

计算性质

• 辛醇/水分配系数(LogP)：
  4.84
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.08
• 氢给体数：
  0.0
• 氢受体数：
  4.0

安全信息

• 危险等级：
  6.1
• 危险类别码：
  R20/21/22,R36/37/38
• 危险品运输编号：
  UN 2811
• 海关编码：
  2930909090
• 包装等级：
  II
• 危险类别：
  6.1
• 安全说明：
  S26,S36/37/39

反应信息

• 作为反应物：
  描述：

  4-Phenylazophenyl isothiocyanate 以88%的产率得到amino{[4-(phenyldiazenyl)phenyl]amino}methane-1-thione
  参考文献：
  名称：

  Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors

  摘要：

  本发明涉及以下式的化合物： 其中X为O、S或NR7，R1-R7、Y和Z如规范中所述，并且其水合物、溶剂合物或药用可接受的盐也被描述。还描述了制备上述式化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、纤溶酶和尿激酶。其中某些化合物表现出对尿激酶的直接、选择性抑制，或者是用于形成具有这种活性的化合物的中间体。

  公开号：

  US06291514B1
• 作为产物：
  描述：

  硫光气 、 4-phenyldiazenylaniline,hydrochloride 在 碳酸氢钠 作用下， 以 氯仿 为溶剂， 反应 0.5h， 生成 4-Phenylazophenyl isothiocyanate
  参考文献：
  名称：

  Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors

  摘要：

  The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino- 1,3-thiazolyl]-thiophene-2-carboxamidine is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00102-0

文献信息

• Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06291514B1

  公开（公告）日：2001-09-18

  The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.

  本发明涉及以下式的化合物： 其中X为O、S或NR7，R1-R7、Y和Z如规范中所述，并且其水合物、溶剂合物或药用可接受的盐也被描述。还描述了制备上述式化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、纤溶酶和尿激酶。其中某些化合物表现出对尿激酶的直接、选择性抑制，或者是用于形成具有这种活性的化合物的中间体。
• Compounds and compositons for treating C1s-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020037915A1

  公开（公告）日：2002-03-28

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are defined in the specification.

  揭示了一种治疗急性或慢性疾病症状的方法，该疾病是由补体级联的经典途径介导的，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4、X、Y和Z。
• Highly chemoselective difluoromethylative homologation of iso(thio)cyanates: expeditious access to unprecedented α,α-difluoro(thio)amides
  作者：Margherita Miele、Rosarita D’Orsi、Vellaisamy Sridharan、Wolfgang Holzer、Vittorio Pace

  DOI：10.1039/c9cc06929a

  日期：——

  The new motif – α,α-difluoromethyl thioamide – has been assembled starting from isothiocyanate (as thioamide precursor) and a formal difluoromethyl-carbanion generated from commercially available TMSCHF₂.

  新的主题 - α,α-二氟甲硫酰胺 - 已经从异硫氰酸酯（作为硫酰胺前体）和从商业上可获得的TMSCHF₂生成的二氟甲基碳负离子开始组装。
• Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides
  申请人：Bukvic Krajacic Mirjana

  公开号：US20080200404A1

  公开（公告）日：2008-08-21

  Novel 9a-N′-substituted-carbamoyl- and thiocarbamoyl-aminoalkyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds having antimalarial activity are claimed. More particularly, the invention relates to 9a-N′-substituted-carbamoyl- and thiocarbamoyl-β-aminoethyl- or -γ-aminopropyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds and to pharmaceutically acceptable derivatives thereof having antimalarial activity.

  本发明涉及具有抗疟活性的9a-N'-取代-氨基甲酰基和硫代氨基甲酰基-氨基烷基-9a-氮杂-9-去氧-9-二氢-9a-同源红霉素A和3-O-去氯基-9a-氮杂-9-去氧-9-二氢-9a-同源红霉素A化合物。更具体地，该发明涉及具有抗疟活性的9a-N'-取代-氨基甲酰基和硫代氨基甲酰基-β-氨基乙基或-γ-氨基丙基-9a-氮杂-9-去氧-9-二氢-9a-同源红霉素A和3-O-去氯基-9a-氮杂-9-去氧-9-二氢-9a-同源红霉素A化合物及其具有抗疟活性的药用可接受衍生物。
• Antiproliferative 1,2,3-thiadiazole compounds
  申请人：——

  公开号：US20030096848A1

  公开（公告）日：2003-05-22

  Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are 1,2,3-thiadiazoles having the structure: 1 and including stereoisomers, solvates, and pharmaceutically acceptable salts thereof, wherein each of R 1 , R 2 , R 3 and R 4 is independently selected from hydrogen, R 5 , R 6 , and R 7 ; R 5 is selected from alkyl, heteroalkyl, aryl and heteroaryl; R 6 is selected from (R 5 ) n -alkylene, (R 5 ) n -heteroalkylene, (R 5 ) n -arylene and (R 5 ) n -heteroarylene; R 7 is selected from (R 6 ) n -alkylene, (R 6 ) n -heteroalkylene, (R 6 ) n -arylene, and (R 6 ) n -heteroarylene; and n is selected from 0, 1, 2, 3, 4 and 5, where R 1 and R 2 may together form a heterocyclic structure including the nitrogen to which they are both attached, and R 3 and R 4 may together form a heterocyclic structure including the nitrogen to which they are both attached; and each of L 1 and L 2 is independently selected from -A1-A2-A3- where each of A1, A2, and A3 is independently selected from a direct bond, alkylene, heteroalkylene, arylene and heteroarylene.

  提供药物组合物和化合物。本发明的化合物具有抗增殖活性，可能促进缺乏正常细胞周期和死亡调节的细胞凋亡。在本发明的一个实施例中，提供了与生理可接受载体结合的化合物配方。这些药物配方在治疗过度增殖性疾病方面很有用，这些疾病包括肿瘤生长、淋巴增殖性疾病和血管生成。本发明的化合物是具有以下结构的1,2,3-噻二唑：1，包括立体异构体、溶剂化合物和其药用可接受盐，其中R1、R2、R3和R4中的每一个都是独立选择的氢、R5、R6和R7；R5选择自烷基、杂原子烷基、芳基和杂芳基；R6选择自（R5）n-烷基、（R5）n-杂原子烷基、（R5）n-芳基和（R5）n-杂芳基；R7选择自（R6）n-烷基、（R6）n-杂原子烷基、（R6）n-芳基和（R6）n-杂芳基；n选择自0、1、2、3、4和5，其中R1和R2可以共同形成包括它们共同连接的氮的杂环结构，R3和R4可以共同形成包括它们共同连接的氮的杂环结构；L1和L2中的每一个都是独立选择自-A1-A2-A3-，其中A1、A2和A3中的每一个都是独立选择自直接键、烷基、杂原子烷基、芳基和杂芳基。